FibroQ: An easy and useful noninvasive test for predicting liver fibrosis in patients with chronic viral hepatitis

Chang Gung Medical Journal

Volumn 32, Issue 6, 2009, Pages 614-622

  Hsieh, Yung Yu ^a   Tung, Shui Yi ^a,b   Lee, I Lin ^a   Lee, Kamfai ^a   Shen, Chien Heng ^a   Wei, Kuo Liang ^a   Chang, Te Sheng ^a   Chuang, Chia Sheng ^a   Wu, Cheng Shyong ^a,b   Lin, Yi Hsiung ^c  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^b CHANG GUNG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Taiwan)

^c DIWAN COLLEGE OF MANAGEMENT   (Taiwan)

Author keywords

Aspartate aminotransferase to platelet ratio index (APRI); Aspartate aminotransferase alanine aminotransferase ratio (AAR); FibroQ; Liver fibrosis; Noninvasive test

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE;

ADULT; AGED; ARTICLE; CHRONIC DISEASE; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; FEMALE; FIBRO QUOTIENT; HUMAN; INTERNATIONAL NORMALIZED RATIO; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; METAVIR FIBROSIS SCORE; PROTHROMBIN TIME; SCORING SYSTEM; THROMBOCYTE COUNT; VIRUS HEPATITIS;

ADULT; AGED; ALANINE TRANSAMINASE; ASPARTATE AMINOTRANSFERASES; COHORT STUDIES; FEMALE; HEPATITIS, CHRONIC; HEPATITIS, VIRAL, HUMAN; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; ROC CURVE;

EID: 74949115003     PISSN: 20720939     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Lu SN, Chue PY, Chen HC, Wu MH, Chen IL, Huang JF, Wang JH, Peng CF, Shih CH, You SL, Lu CF, Chen CJ, Chang WY. Different viral aetiology of hepatocellular carcinoma between two hepatitis B and C endemic townships in Taiwan. J Gastroenterol Hepatol 1997;12:547-50.
2. Benhamou JP, Rodes J, Alter H, Bismuth H, Desmet V, Guardia J, Heathcote J, Lok A, Maddrey WC, Btischenfelde KHMZ, Pagliaro L, Paumgartner G, Sherlock S. EASL International Consensus Conference on hepatitis C. Paris, 26-27 February 1999. Consensus statement. J Hepatol 1999;31:3-8.
3. Boyer JL, Muggia FM, Chang EB, Collyar DE, DeLeve LD, Feinberg J, Judge TA, Shapiro CL, Spector SA, Suchy FJ, Tomsko PL, Turner BJ. National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C. 10-12 June, 2002. Hepatology 2002;36:S3-15.
4. Yano M, Kumada H, Hage M, Ikeda K, Shimamatsu K, Inoue O, Hashimoto E, Lefkowitch JH, Ludwig J, Okuda K. The long-term pathological evolution of chronic hepatitis C. Hepatology 1996;23:1334-40.
5. Pawlotsky JM. Current and future concepts in hepatitis C therapy. Semin Liver Dis 2005;25:72-83.
6. Bedossa P, Dargere D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003;38:1449-57.
7. Cadranel JF, Rufat P, Degos F. Practices of liver biopsy in France: results of a prospective nationwide survey. For the Group of Epidemiology of the French Association for the Study of the Liver (AFEF). Hepatology 2000;32:477-81.
8. Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, Lok ASF. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003;38:518-26.
9. Lieber CS, Weiss DG, Morgan TR, Paronetto F. Aspartate aminotransferase to platelet ratio index in patients with alcoholic liver fibrosis. Am J Gastroenterol 2006;101:1500-8.
10. Parise ER, Oliveira AC, Figueiredo-Mendes C, Lanzoni V, Martins J, Nader H, Ferraz ML. Noninvasive serum markers in the diagnosis of structural liver damage in chronic hepatitis C virus infection. Liver Int 2006;26:1095-9.
11. Wilson LE, Torbenson M, Astemborski J, Faruki H, Spoler C, Rai R, Mehta S, Kirk GD, Nelson K, Afdhal N, Thomas DL. Progression of liver fibrosis among injection drug users with chronic hepatitis C. Hepatology 2006;43:788-95.
12. Lackner C, Struber G, Liegl B, Leibl S, Ofner P, Bankuti C, Bauer B, Stauber RE. Comparison and validation of simple noninvasive tests for prediction of fibrosis in chronic hepatitis C. Hepatology 2005;41:1376-82.
13. Williams AL, Hoofnagle JH. Ratio of serum aspartate to alanine aminotransferase in chronic hepatitis Relationship to cirrhosis. Gastroenterology 1988;95:734-9.
14. Sheth SG, Flamm SL, Gordon FD, Chopra S. AST/ALT ratio predicts cirrhosis in patients with chronic hepatitis C virus infection. Am J Gastroenterol 1998;93:44-8.
15. Reedy DW, Loo AT, Levine RA. AST/ALT ratio > or = 1 is not diagnostic of cirrhosis in patients with chronic hepatitis C. Dig Dis Sci 1998;43:2156-9.
16. Park GJ, Lin BP, Ngu MC, Jones DB, Katelaris PH. Aspartate aminotransferase: alanine aminotransferase ratio in chronic hepatitis C infection: is it a useful predictor of cirrhosis? J Gastroenterol Hepatol 2000;15:386-90.
17. Imperiale TF, Said AT, Cummings OW, Born LJ. Need for validation of clinical decision aids: use of the AST/ALT ratio in predicting cirrhosis in chronic hepatitis C. Am J Gastroenterol 2000;95:2328-32.
18. Giannini E, Risso D, Botta F, Chiarbonello B, Fasoli A, Malfatti F, Romagnoli P, Testa E, Ceppa P, Testa R. Validity and clinical utility of the aspartate aminotransferase-alanine aminotransferase ratio in assessing disease severity and prognosis in patients with hepatitis C virusrelated chronic liver disease. Arch Intern Med 2003;163:218-24.
19. Bedossa P, Bioulac-Sage P, Callard P, Chevallier M, Degott C, Deugnier Y, Fabre M, Reynes M, Voigt JJ, Zafrani ES, Poynard T, Babany G; The French METAVIR Cooperative Study Group. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology 1994;20:15-20.
20. Hanley JA, McNeil BJ. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 1983;148:839-43.
21. Pohl A, Behling C, Oliver D, Kilani M, Monson P, Hassanein T. Serum aminotransferase levels and platelet counts as predictors of degree of fibrosis in chronic hepatitis C virus infection. Am J Gastroenterol 2001;96:3142-6.
22. Forns X, Ampurdanes S, Llovet JM, Aponte J, Quinto L, Martinez-Bauer E, Bruguera M, Sanchez-Tapias JM, Rodes J. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology 2002;36:986-92.
23. Cales P, Oberti F, Michalak S, Hubert-Fouchard I, Rousselet MC, Konate A, Gallois Y, Ternisien C, Chevailler A, Lunel F. A novel panel of blood markers to assess the degree of liver fibrosis. Hepatology 2005;42:1373-81.
24. Trocme C, Leroy V, Stunn N, Hilleret MN, Bottari S, Morel F, Zarski JP. Longitudinal evaluation of a fibrosis index combining MMP-I and PIIINP compared to MMP-9, TIMP-1 and hyaluronic acid in patients with chronic hepatitis C treated by interferon-alpha and ribavirin. J Viral Hepat 2006;13:643-51.
25. Leroy V, Hilleret MN, Stunn N, Trocme C, Renversez JC, Faure P, Morel F, Zarski JP. Prospective comparison of six non-invasive scores for the diagnosis of liver fibrosis in chronic hepatitis C. J Hepatol 2007;46:775-82.
26. Shaheen AA, Myers RP. Diagnostic accuracy of the aspartate aminotransferase-to-platelet ratio index for the prediction of hepatitis C-related fibrosis: a systematic review. Hepatology 2007;46:912-21.
27. Liu CH, Lin JW, Tsai FC, Yang PM, Lai MY, Chen JH, Kao JH, Chen DS. Noninvasive tests for the prediction of significant hepatic fibrosis in hepatitis C virus carriers with persistently normal alanine aminotransferases. Liver Int 2006;26:1087-94.